Free Access
Issue
J Extra Corpor Technol
Volume 52, Number 1, March 2020
Page(s) 63 - 70
DOI https://doi.org/10.1051/ject/202052063
Published online 15 March 2020
  1. Howell WH, Holt E Two new factors in blood coagulation – heparin and pro antithrombin. Am J Physiol. 1918;47:328–41. [CrossRef] [Google Scholar]
  2. Chargaff E, Olson K Studies on the action of heparin and other anticoagulation. The influence of protamine on the anticoagulant effect in vivo. J Biol Chem. 1937;122:153–67. [CrossRef] [Google Scholar]
  3. Hoenicka M, Rupp P, Muller-Eising K, et al. Anticoagulation management during multivessel coronary artery bypass grafting: A randomized trial comparing individualized heparin management and conventional hemostasis management. J Thromb Haemost. 2015;13:1196–206. [CrossRef] [PubMed] [Google Scholar]
  4. Koster A, Borgermann J, Gummert J, et al. Protamine overdose and its impact on coagulation, bleeding, and transfusions after cardiopulmonary bypass: Results of a randomized double-blind controlled pilot study. Clin Appl Thromb Hemost. 2014;20:290–5. [CrossRef] [PubMed] [Google Scholar]
  5. Meesters MI, Veerhoek D, de Lange F, et al. Effect of high or low protamine dosing on postoperative bleeding following heparin anticoagulation in cardiac surgery. A randomised clinical trial. Thromb Haemost. 2016;116:251–61. [CrossRef] [PubMed] [Google Scholar]
  6. Kunz SA, Miles LF, Ianno DJ, et al. The effect of protamine dosing variation on bleeding and transfusion after heparinisation for cardiopulmonary bypass. Perfusion. 2018;33:445–52. [CrossRef] [PubMed] [Google Scholar]
  7. Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA), Boer C, et al. 2017 EACTS/EACTA guidelines on patient blood management for adult cardiac surgery. J Cardiothorac Vasc Anesth. 2018;32:88–120. [CrossRef] [PubMed] [Google Scholar]
  8. Boer C, Meesters MI, Veerhoek D, et al. Anticoagulant and side-effects of protamine in cardiac surgery: A narrative review. Br J Anaesth. 2018;120:914–27. [CrossRef] [PubMed] [Google Scholar]
  9. St Ange K, Onishi A, Fu L, et al. Analysis of heparins derived from bovine tissues and comparison to porcine intestinal heparins. Clin Appl Thromb Hemost. 2016;22:520–7. [CrossRef] [PubMed] [Google Scholar]
  10. Blossom DB, Kallen AJ, Patel PR, et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med. 2008;359:2674–84. [CrossRef] [PubMed] [Google Scholar]
  11. Smythe MA, Nutescu EA, Wittkowsky AK Changes in the USP heparin monograph and implications for clinicians. Pharmacotherapy. 2010;30:428–31. [CrossRef] [PubMed] [Google Scholar]
  12. Anderson DA, Holt DW Has the new USP assay for heparin affected dosage for patients undergoing cardiopulmonary bypass? J Extra Corpor Technol. 2013;45:112–5. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  13. Finley A, Greenberg C Review article: Heparin sensitivity and resistance: Management during cardiopulmonary bypass. Anesth Analg. 2013;116:1210–22. [CrossRef] [PubMed] [Google Scholar]
  14. Tollefsen DM, Majerus DW, Blank MK Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem. 1982;257:2162–9. [CrossRef] [PubMed] [Google Scholar]
  15. Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e24S–43S. [CrossRef] [PubMed] [Google Scholar]
  16. Hattersley PG Activated coagulation time of whole blood. JAMA. 1966;196:436–40. [CrossRef] [PubMed] [Google Scholar]
  17. Wolberg AS, Meng ZH, Monroe DM3rd, et al. A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma. 2004;56:1221–8. [CrossRef] [PubMed] [Google Scholar]
  18. Mochizuki T, Olson PJ, Szlam F, et al. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg. 1998;87:781–5. [CrossRef] [PubMed] [Google Scholar]
  19. Stau T, Metz J, Taugner R Exogenous 35S-labeled heparin: Organ distribution and metabolism. Naunyn Schmiedebergs Arch Pharmacol. 1973;280:93–102. [CrossRef] [PubMed] [Google Scholar]
  20. de Swart CA, Nijmeyer B, Roelofs JM, et al. Kinetics of intravenously administered heparin in normal humans. Blood. 1982;60:1251–8. [CrossRef] [PubMed] [Google Scholar]
  21. Olsson P, Lagergren H, Ek S The elimination from plasma of intravenous heparin. An experimental study on dogs and humans. Acta Med Scand. 1963;173:619–30. [Google Scholar]
  22. Dawes J, Papper DS Catabolism of low-dose heparin in man. Thromb Res 1979;14:845–60. [CrossRef] [PubMed] [Google Scholar]
  23. Zaidan JR, Johnson S, Brynes R, et al. Rate of protamine administration: Its effect on heparin reversal and antithrombin recovery after coronary artery surgery. Anesth Analg. 1986;65:377–80. [Google Scholar]
  24. Besser MW, Klein AA The coagulopathy of cardiopulmonary bypass. Crit Rev Clin Lab Sci. 2010;47:197–212. [CrossRef] [PubMed] [Google Scholar]
  25. Demma L, Levy JH A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass. Anesth Analg. 2012;115:1273–8. [CrossRef] [PubMed] [Google Scholar]
  26. Chandler WL Effects of hemodilution, blood loss, and consumption on hemostatic factor levels during cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2005;19:459–67. [CrossRef] [PubMed] [Google Scholar]
  27. Castaneda AR Must heparin be neutralized following open-heart operations? J Thorac Cardiovasc Surg. 1966;52:716–24. [CrossRef] [PubMed] [Google Scholar]
  28. Campbell FW, Goldstein MF, Atkins PC Management of the patient with protamine hypersensitivity for cardiac surgery. Anesthesiology. 1984;61:761–4. [CrossRef] [PubMed] [Google Scholar]
  29. Butterworth J, Lin YA, Prielipp R, et al. The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. Anesth Analg. 2002;94:514–22. [CrossRef] [PubMed] [Google Scholar]
  30. Sokolowska E, Kalaska B, Miklosz J, et al. The toxicology of heparin reversal with protamine: Past, present and future. Expert Opin Drug Metab Toxicol. 2016;12:897–909. [CrossRef] [PubMed] [Google Scholar]
  31. Kitani T, Nagarajan SC, Shanberge JN Effect of protamine on heparin-antithrombin III complexes. In vitro studies. Thromb Res. 1980;17:367–74. [CrossRef] [PubMed] [Google Scholar]
  32. Okajima Y, Kanayama S, Maeda Y, et al. Studies on the neutralizing mechanism of antithrombin activity of heparin by protamine. Thromb Res. 1981;24:21–9. [CrossRef] [PubMed] [Google Scholar]
  33. Kitani T, Nagarajan SC, Shanberge JN Effect of protamine on heparin antithrombin III complexes. In vivo studies. Thromb Res. 1980;17:375–82. [CrossRef] [PubMed] [Google Scholar]
  34. Lindblad B, Wakefield TW, Whitehouse WMJr, et al. The effect of protamine sulfate on platelet function. Scand J Thorac Cardiovasc Surg. 1988;22:55–9. [CrossRef] [PubMed] [Google Scholar]
  35. Ammar T, Fisher CF The effects of heparinase 1 and protamine on platelet reactivity. Anesthesiology. 1997;86:1382–6. [CrossRef] [PubMed] [Google Scholar]
  36. Kalaska B, Sokolowska E, Kaminski K, et al. Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis. Eur J Pharmacol. 2012;686:81–9. [CrossRef] [PubMed] [Google Scholar]
  37. Panzer S, Schiferer A, Steinlechner B, et al. Serological features of antibodies to protamine inducing thrombocytopenia and thrombosis. Clin Chem Lab Med. 2015;53:249–55. [CrossRef] [PubMed] [Google Scholar]
  38. Shigeta O, Kojima H, Hiramatsu Y, et al. Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1999;118:354–60. [CrossRef] [PubMed] [Google Scholar]
  39. Nielsen VG Protamine enhances fibrinolysis by decreasing clot strength: Role of tissue factor-initiated thrombin generation. Ann Thorac Surg. 2006;81:1720–7. [CrossRef] [PubMed] [Google Scholar]
  40. Ni Ainle F, Preston RJS, Jenkins PV, et al. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood. 2009;114:1658–65. [CrossRef] [PubMed] [Google Scholar]
  41. Godal BHC The interaction of protamine with human fibrinogen and the significance of this interaction for the coagulation of fibrinogen. Scand J Clin Lab Invest. 1960;12:433–45. [CrossRef] [PubMed] [Google Scholar]
  42. Temperley IJ The precipitation of fibrinogen by heparin at ph 4.8. Ir J Med Sci. 2008;38:159. [Google Scholar]
  43. Park KW Protamine and protamine reactions. Int Anesthesiol Clin. 2004;42:135–45. [CrossRef] [PubMed] [Google Scholar]
  44. Velders AJ, Wildevuur CR Platelet damage by protamine and the protective effect of prostacyclin: An experimental study in dogs. Ann Thorac Surg. 1986;42:168–71. [CrossRef] [PubMed] [Google Scholar]
  45. Falter F, Razzaq N, John M, et al. Clinical evaluation of measuring the ACT during elective cardiac surgery with two different devices. J Extra Corpor Technol. 2018;50:38–43. [PubMed] [Google Scholar]
  46. Teoh KH, Young E, Blackall MH, et al. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? J Thorac Cardiovasc Surg. 2004;128:211–9. [CrossRef] [PubMed] [Google Scholar]
  47. Levy JH, Schwieger IM, Zaidan JR, et al. Evaluation of patients at risk for protamine reactions. J Thorac Cardiovasc Surg. 1989;98:200–4. [CrossRef] [PubMed] [Google Scholar]
  48. Valchanov K, Falter F, George S, et al. Three cases of anaphylaxis to protamine: Management of anticoagulation reversal. J Cardiothorac Vasc Anesth. 2019;33:482–6. [CrossRef] [PubMed] [Google Scholar]
  49. Shore-Lesserson L, Baker RA, Ferraris VA, et al. The Society of Thoracic Surgeons, the Society of Cardiovascular Anesthesiologists, and the American Society of ExtraCorporeal Technology: Clinical practice guidelines-anticoagulation during cardiopulmonary bypass. Ann Thorac Surg. 2018;105:650–62. [CrossRef] [PubMed] [Google Scholar]
  50. Shore-Lesserson L Coagulation monitoring. In: Kaplan J, ed. Kaplans’ Cardiac Anesthesia, 7th ed. Philadelphia, PA: Elsevier; 2016:698–730. [Google Scholar]
  51. Despotis GJ, Joist JH, Hogue CW, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1995;110:46–54. [CrossRef] [PubMed] [Google Scholar]
  52. Raymond PD, Ray MJ, Callen SN, et al. Heparin monitoring during cardiac surgery. Part 1: Validation of whole-blood heparin concentration and activated clotting time. Perfusion. 2003;18:269–76. [CrossRef] [PubMed] [Google Scholar]
  53. Wang J, Ma HP, Zheng H Blood loss after cardiopulmonary bypass, standard vs titrated protamine: A meta-analysis. Neth J Med. 2013;71:123–7. [PubMed] [Google Scholar]
  54. Avidan MS, Alcock EL, Da Fonseca J, et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth. 2004;92:178–86. [CrossRef] [PubMed] [Google Scholar]
  55. Slight RD, Buell R, Nzewi OC, et al. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2008;22:47–52. [CrossRef] [PubMed] [Google Scholar]
  56. Radulovic V, Laffin A, Hansson KM, et al. Heparin and protamine titration does not improve haemostasis after cardiac surgery: A prospective randomized study. PLoS One. 2015;10:e0130271. [CrossRef] [PubMed] [Google Scholar]
  57. Gilly G, Trusheim J Con: The hepcon HMS should not be used instead of traditional activated clotting time to dose heparin and protamine for cardiac surgery requiring cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2016;30:1730–2. [CrossRef] [PubMed] [Google Scholar]
  58. Bull BS, Huse WM, Brauer FS, et al. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg. 1975;69:685–9. [CrossRef] [PubMed] [Google Scholar]
  59. Suarez Cuenca J, Gayoso Diz P, Gude Sampedro F, et al. Method to calculate the protamine dose necessary for reversal of heparin as a function of activated clotting time in patients undergoing cardiac surgery. J Extra Corpor Technol. 2013;45:235–41. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  60. Davidsson FO, Johagen D, Appelblad M, et al. Reversal of heparin after cardiac surgery: Protamine titration using a statistical model. J Cardiothorac Vasc Anesth. 2015;29:710–4. [CrossRef] [PubMed] [Google Scholar]
  61. Hallgren O, Svenmarker S, Appelblad M Implementing a statistical model for protamine titration: Effects on coagulation in cardiac surgical patients. J Cardiothorac Vasc Anesth. 2017;31:516–21. [CrossRef] [PubMed] [Google Scholar]
  62. Miles LF, Marchiori P, Falter F Pilot validation of an individualised pharmacokinetic algorithm for protamine dosing after systemic heparinisation for cardiopulmonary bypass. Perfusion. 2017;32:481–8. [CrossRef] [PubMed] [Google Scholar]
  63. Meesters MI, Veerhoek D, de Jong JR, et al. A pharmacokinetic model for protamine dosing after cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2016;30:1190–5. [CrossRef] [PubMed] [Google Scholar]
  64. Watanabe J, Hori K, Iwamoto K, et al. Disposition of tritium-labelled heparin in rats. J Pharmacobiodyn. 1982;5:627–37. [CrossRef] [PubMed] [Google Scholar]
  65. Baglin T, Barrowcliffe TW, Cohen A, et al. Guidelines on the use and monitoring of heparin. Br J Haematol. 2006;133:19–34. [CrossRef] [PubMed] [Google Scholar]
  66. Despotis GJ, Filos KS, Zoys TN, et al. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: A multivariate analysis in cardiac surgical patients. Anesth Analg. 1996;82:13–21. [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.